the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering.oIf this form is a post-effective amendment filed pursuant
registration statement for the same offering.oIf this form is a post-effective amendment filed pursuant
the Securities Act registration statement number of the earlier effective
the Securities Act registration statement number of the earlier effective
page 24 of this prospectus.Our common stock is listed on the Nasdaq Global Market under the symbol “ACOR.”  On November 17, 2006, the last reported sales
Our marketed product, Zanaflex Capsules, is FDA-approved for the
for future product launches, in addition to generating product revenue.In April 2005, we launched Zanaflex Capsules, a new
sales and marketing activities, clinical and preclinical development programs
meaningful revenue from this product will be adversely affected.5Our company has limited sales and marketing experience and
product candidates sufficient to obtain regulatory marketing approval are
effect on our business.If any additional studies are required by the FDA for Fampridine-SR,
conduct clinical trials to obtain FDA approval to commercialize any product
adversely affect our results of operations.8If our competitors develop and market products that are more
product development activities, and could require substantial funding to
misuse of Zanaflex Capsules or any other FDA-approved products we may sell in
stockholders sell a large number of shares of our common stock, or the public
market perceives that existing stockholders might sell shares of common stock,
pledgees or secured parties may offer and sell the shares of common stock, from
registration of the shares of common stock offered by this prospectus.We have agreed
the shares of common stock, including registration and filing fees, printing